BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
1.2.1 Chronic heart failure						
AWAKE-HF 2019	0	69	1	70	0.1%	0.34 [0.01, 8.16]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	1	231	1	232	0.1%	1.00 [0.06, 15.96]
Li J 2019 (1)	3	62	5	64	0.4%	0.62 [0.15, 2.48]
OUTSTEP-HF	1	309	4	310	0.2%	0.25 [0.03, 2.23]
PARADIGM-HF 2014	729	4203	848	4229	97.9%	0.86 [0.79, 0.95]
PRIME-HF 2019	1	60	0	58	0.1%	2.90 [0.12, 69.81]
Subtotal (95% CI)		**4942**		**4971**	**98.7%**	**0.86 [0.79, 0.94]**
Total events	735		859			
Heterogeneity: Tau² = 0.00; Chi² = 2.35, df = 5 (P = 0.80); I² = 0%						
Test for overall effect: Z = 3.26 (P = 0.001)						
1.2.2 Acute heart failure						
PIONEER-HF 2018	10	440	15	441	1.3%	0.67 [0.30, 1.47]
Subtotal (95% CI)		**440**		**441**	**1.3%**	**0.67 [0.30, 1.47]**
Total events	10		15			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.00 (P = 0.32)						
Total (95% CI)		**5382**		**5412**	**100.0%**	**0.86 [0.79, 0.94]**
Total events	745		874			
Heterogeneity: Tau² = 0.00; Chi² = 2.75, df = 6 (P = 0.84); I² = 0%						
Test for overall effect: Z = 3.36 (P = 0.0008)						
Test for subgroup differences: Chi² = 0.40, df = 1 (P = 0.53), I² = 0%